China Universal Asset Management Co. Ltd. Has $432,000 Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

China Universal Asset Management Co. Ltd. grew its position in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 10.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,547 shares of the company’s stock after buying an additional 892 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Apogee Therapeutics were worth $432,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Apogee Therapeutics in the 3rd quarter valued at about $71,000. JPMorgan Chase & Co. boosted its stake in shares of Apogee Therapeutics by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock valued at $1,736,000 after purchasing an additional 1,212 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Apogee Therapeutics by 22.2% during the 4th quarter. SG Americas Securities LLC now owns 9,890 shares of the company’s stock worth $448,000 after buying an additional 1,796 shares during the period. Finally, Handelsbanken Fonder AB raised its stake in shares of Apogee Therapeutics by 25.7% during the third quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $517,000 after buying an additional 1,800 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

Analysts Set New Price Targets

APGE has been the subject of a number of analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Wedbush increased their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Finally, Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $89.71.

Insider Transactions at Apogee Therapeutics

In other news, Director Mark C. Mckenna purchased 20,000 shares of Apogee Therapeutics stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $49.54 per share, with a total value of $990,800.00. Following the transaction, the director now directly owns 20,000 shares in the company, valued at $990,800. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Carl Dambkowski sold 4,085 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $46.94, for a total transaction of $191,749.90. Following the transaction, the insider now directly owns 255,348 shares of the company’s stock, valued at $11,986,035.12. This represents a 1.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,955 shares of company stock valued at $3,433,962 over the last quarter. Corporate insiders own 36.10% of the company’s stock.

Apogee Therapeutics Trading Down 2.7 %

APGE stock opened at $41.36 on Monday. Apogee Therapeutics, Inc. has a 1-year low of $32.78 and a 1-year high of $72.29. The firm has a market cap of $1.86 billion, a PE ratio of -17.09 and a beta of 2.26. The business’s 50-day moving average price is $44.62 and its two-hundred day moving average price is $48.80.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.13). On average, analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.